CaliPharms, Inc. (KGET) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CaliPharms, Inc. (KGET) trades at $0.00004 with AI Score 57/100 (Grade B). CaliPharms, Inc. is a US-based company focused on the medicinal cannabis industry, specifically THC and CBD beverages. Sector: Basic materials.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for KGET: KGET does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KGET against Basic Materials peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KGET: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
CaliPharms, Inc. (KGET) Materials & Commodity Exposure
CaliPharms, Inc. operates within the evolving medicinal cannabis sector, concentrating on THC and CBD-infused beverages. The company, formerly Kleangas Energy Technologies, shifted its focus in 2017. It faces competition in a dynamic market while striving to establish its brand in the cannabis beverage segment.
What Is the Investment Thesis for KGET?
CaliPharms, Inc. presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. The company's success hinges on its ability to navigate complex regulatory hurdles and establish a strong brand presence. Key value drivers include successful product development, effective marketing, and strategic partnerships. The company's negative P/E ratio of -0.01 and a profit margin of -11861.4% indicate significant financial challenges. Investors should closely monitor the company's cash flow, debt levels, and ability to secure funding for future growth. The high beta of -58.74 suggests extreme volatility relative to the market.
Based on FMP financials and quantitative analysis
KGET Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.01 reflects the company's current lack of profitability.
- Profit Margin of -11861.4% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of 100.0% suggests high potential profitability if operational costs are managed effectively.
- Beta of -58.74 indicates an extremely volatile stock, moving inversely to the market.
Who Are KGET's Competitors?
KGET is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FMTOF Femto Technologies Inc. | $0.71 | +0.00% | 47 | |
| AGRZ Agroz Inc. | $0.33 | +3.74% | $7.15M | 47 |
| SEED Origin Agritech Limited | $1.02 | -0.58% | $12.4M | 41 |
| MGROF MustGrow Biologics Corp. | $0.31 | +0.00% | $20.0M | 54 |
| ARLSF Argo Graphene Solutions Corp. | $0.82 | +1.23% | $20.8M | 44 |
| EDNSF Eden Research plc | $0.04 | +0.00% | $28.1M | 54 |
| BIOX Bioceres Crop Solutions Corp. | $0.45 | +8.49% | $28.5M | 42 |
| HMIFF Harvest Minerals Limited | $0.06 | +0.00% | $29.7M | 41 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KGET's Key Strengths?
Focus on the growing cannabis beverage market.
- Potential for first-mover advantage in specific regions.
- Experienced management team with knowledge of the cannabis industry.
What Are KGET's Weaknesses?
Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for growth.
- Lack of established brand recognition.
What Could Drive KGET Stock Higher?
KGET catalyst: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
- Increasing consumer acceptance of cannabis-infused beverages could drive demand and revenue growth.
- Development and launch of new cannabis-infused beverage products could attract new customers.
- Securing partnerships with established beverage distributors could expand market reach.
- Positive clinical trial results for cannabis-based therapies could increase investor confidence.
What Are the Key Risks for KGET?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Stringent regulations and licensing requirements could limit market access.
- Intense competition from larger cannabis companies could erode market share.
- Negative public perception of cannabis could hinder demand growth.
- Limited access to capital and funding could constrain growth plans.
- Product recalls or safety concerns could damage brand reputation.
What Are the Growth Opportunities for KGET?
- Expansion into New Markets: As cannabis legalization expands across the United States, CaliPharms, Inc. has the opportunity to enter new markets. Each new state represents a potential revenue stream, provided the company can navigate the local regulatory environment. The timeline for this growth is dependent on the pace of legalization efforts and the company's ability to secure licenses and distribution agreements.
- Product Diversification: CaliPharms, Inc. can expand its product line beyond THC and CBD beverages to include other cannabis-infused products, such as edibles, topicals, and concentrates. This diversification would allow the company to cater to a wider range of consumer preferences and increase its market share. The timeline for product diversification depends on the company's R&D capabilities and its ability to obtain regulatory approval for new products. The market for cannabis-infused products is diverse and growing rapidly.
- Strategic Partnerships: Forming strategic partnerships with established beverage distributors or cannabis retailers can provide CaliPharms, Inc. with access to wider distribution networks and increased brand visibility. These partnerships can accelerate the company's growth and reduce its reliance on direct sales. The timeline for establishing strategic partnerships depends on the company's networking efforts and its ability to negotiate favorable terms. The benefits of strategic partnerships can be significant, including increased revenue and market share.
- Branding and Marketing: Investing in branding and marketing efforts can help CaliPharms, Inc. establish a strong brand identity and differentiate itself from competitors. Effective marketing campaigns can increase consumer awareness and drive sales. The timeline for building a strong brand depends on the company's marketing budget and its ability to create compelling messaging. A strong brand can command premium pricing and increase customer loyalty.
- Research and Development: Investing in research and development can enable CaliPharms, Inc. to develop innovative new products and improve the quality and efficacy of its existing products. This can give the company a competitive advantage and attract new customers. The timeline for R&D depends on the company's resources and its ability to conduct successful clinical trials. Successful R&D can lead to patentable products and increased market share.
What Are KGET's Competitive Advantages?
- First-mover advantage in specific regional markets.
- Proprietary formulations for THC and CBD beverages.
- Established relationships with cannabis cultivators and distributors.
What Does KGET Do?
CaliPharms, Inc., headquartered in Temecula, California, is a participant in the United States' medicinal cannabis industry. The company's primary focus is the development and potential distribution of beverages infused with THC and CBD. CaliPharms, Inc. was originally established under the name Kleangas Energy Technologies, Inc., reflecting an earlier business direction. In January 2017, the company underwent a strategic shift, rebranding itself as CaliPharms, Inc. to align with its new focus on the cannabis market. This transition marked a significant change in business strategy, moving away from energy technologies to capitalize on the emerging opportunities within the medicinal cannabis sector. The company is positioning itself to cater to the growing demand for cannabis-infused products, particularly in the beverage segment. CaliPharms, Inc. is working to establish its presence in a competitive market, navigating the regulatory landscape and consumer preferences within the cannabis industry.
What Products and Services Does KGET Offer?
- Engages in the medicinal cannabis industry in the United States.
- Focuses on the development of THC and CBD beverages.
- Aims to capitalize on the growing market for cannabis-infused products.
- Navigates the regulatory landscape of the cannabis industry.
- Seeks to establish a brand presence in the cannabis beverage segment.
- Works to develop and distribute cannabis-infused beverages.
How Does KGET Make Money?
- Develops and potentially distributes THC and CBD-infused beverages.
- Aims to generate revenue through the sale of these beverages.
- Focuses on the medicinal cannabis market in the United States.
What Industry Does KGET Operate In?
CaliPharms, Inc. operates in the rapidly evolving cannabis industry, specifically targeting the infused beverage market. This sector is characterized by changing regulations, increasing competition, and growing consumer acceptance. The market is driven by the increasing legalization of cannabis for medicinal and recreational purposes in various states. CaliPharms faces competition from established players in the beverage industry and emerging cannabis companies. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Who Are KGET's Key Customers?
- Consumers seeking medicinal cannabis products.
- Individuals interested in THC and CBD-infused beverages.
- Patients with medical conditions that may benefit from cannabis use.
Financial Health
CaliPharms, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
KGET Valuation & Market Position
Relative to its peer group, KGET's quantitative score of 57/100 is above the peer average of 47/100.
Key Financial Metrics
Return on equity for CaliPharms, Inc. stands at 19.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -34.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
CaliPharms, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Temecula, US. The company is led by CEO Eric Watson. KGET has traded publicly since 2013.
KGET Financials
Bull Case vs Bear Case
Bull Case
- Focus on the growing cannabis beverage market.
- Potential for first-mover advantage in specific regions.
- Experienced management team with knowledge of the cannabis industry.
- Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
Bear Case
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for growth.
- Lack of established brand recognition.
- Potential: Stringent regulations and licensing requirements could limit market access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KGET Latest News
No recent news available for KGET.
KGET Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KGET.
Price Targets
Wall Street price target analysis for KGET.
KGET MoonshotScore
What does this score mean?
The MoonshotScore rates KGET 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Agricultural InputsLeadership: Eric Watson
CEO
Eric Watson serves as the Chief Executive Officer of CaliPharms, Inc. Information regarding Mr. Watson's detailed career history, educational background, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive overview of his professional background and qualifications.
Track Record: Due to limited information, it is not possible to assess Eric Watson's track record at CaliPharms, Inc. or his previous accomplishments in other roles. An evaluation of his strategic decisions, company milestones achieved under his leadership, and overall performance requires additional data.
KGET OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CaliPharms, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to less stringent regulations and oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited liquidity and potential for price volatility.
- Lack of regulatory oversight and potential for fraud.
- Uncertainty regarding financial reporting and disclosure.
- Higher risk of delisting or trading suspension.
- Potential for limited access to capital and funding.
- Verify the company's legal status and registration.
- Obtain and review the company's financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Determine the availability of reliable information and disclosures.
- Understand the liquidity and trading characteristics of the stock.
- Company's registration and good standing with regulatory authorities.
- Availability of some financial information, even if limited.
- Active communication with investors and the public.
- Positive media coverage or industry recognition.
- Existence of a functional website and contact information.
What Investors Ask About CaliPharms, Inc. (KGET) — Basic Materials
What does the AI Score mean for KGET?
KGET holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. CaliPharms, Inc. is a US-based company focused on the medicinal cannabis industry, specifically THC and CBD beverages. Formerly known as Kleangas Energy Technologies, it rebranded in 2017 …
What does CaliPharms, Inc. do?
CaliPharms, Inc. is a company operating within the medicinal cannabis industry in the United States. Its primary focus is on the development and potential distribution of beverages infused with THC and CBD. The company aims to capitalize on the growing demand for cannabis-infused products, particularly in the beverage segment, by creating and marketing these specialized drinks. CaliPharms, Inc.
What do analysts say about KGET stock?
There is no available analyst coverage for KGET stock. The company's micro-cap status and OTC listing may contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before investing in KGET, considering the limited information and potential risks associated with the stock. Key valuation metrics to consider include revenue growth, gross margin, and cash flow.
What are the main risks for KGET?
KGET faces several risks inherent to its position as a small company in the cannabis industry. These include intense competition from larger, better-funded companies, the evolving and uncertain regulatory landscape surrounding cannabis, and potential challenges in securing financing for growth.
What are the key factors to evaluate for KGET?
CaliPharms, Inc. (KGET) holds an AI score of 57/100 (moderate). presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. Not financial advice.
How frequently does KGET data refresh on this page?
KGET's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KGET's recent stock price performance?
CaliPharms, Inc. (KGET) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the growing cannabis beverage market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KGET overvalued or undervalued right now?
CaliPharms, Inc. (KGET) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KGET before investing?
Before investing in CaliPharms, Inc. (KGET), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for this company. OTC stocks are inherently riskier.